US CDC Advisory Panel Votes to Limit Hepatitis B Vaccines for Newborns in Regressive Move
The US Centers for Disease Control and Prevention (CDC) advisory panel voted on Friday morning to limit the hepatitis B vaccine for newborns, signaling a major shift away from evidence-based recommendations. The decision is seen as part of the Trump administration's broader effort to undermine vaccination policies.
The panel's recommendation now suggests that parents whose mothers test negative for hepatitis B should decide when or if their child should receive the vaccine series in consultation with a healthcare professional. This change will add confusion to routine vaccinations and create access issues, particularly for lower-income families.
Experts warn that this move could lead to an increase in preventable infections among children, citing estimates that delay the vaccination from birth to two months would result in at least 1,400 new cases of hepatitis B every year. This could ultimately lead to hundreds of liver cancer cases and deaths.
The Hepatitis B Foundation's Michaela Jackson noted that this decision "removes choice by causing barriers to access" and will leave parents unsure who to trust for vaccine recommendations. The change also adds unnecessary complexity, as healthcare providers may interpret the new language as a sign that the vaccine is controversial or carries additional risks.
Independent medical bodies like the American Academy of Pediatrics strongly recommend that all infants receive the hepatitis B vaccine within 24 hours of birth. However, under the new recommendation, parents may delay vaccination, potentially leaving them vulnerable to infection.
The CDC's action aligns with President Trump's stated desire to review and realign child immunization recommendations with best practices from other developed countries. However, this move is seen as a regressive step in public health policy, driven by misinformation and misconceptions about vaccines.
As Cody Meissner, professor of pediatrics at Dartmouth College, noted, "We have heard 'do no harm' is a moral imperative. We are doing harm by changing this wording." The decision highlights the need for evidence-based policies that prioritize public health over politics and special interests.
The US Centers for Disease Control and Prevention (CDC) advisory panel voted on Friday morning to limit the hepatitis B vaccine for newborns, signaling a major shift away from evidence-based recommendations. The decision is seen as part of the Trump administration's broader effort to undermine vaccination policies.
The panel's recommendation now suggests that parents whose mothers test negative for hepatitis B should decide when or if their child should receive the vaccine series in consultation with a healthcare professional. This change will add confusion to routine vaccinations and create access issues, particularly for lower-income families.
Experts warn that this move could lead to an increase in preventable infections among children, citing estimates that delay the vaccination from birth to two months would result in at least 1,400 new cases of hepatitis B every year. This could ultimately lead to hundreds of liver cancer cases and deaths.
The Hepatitis B Foundation's Michaela Jackson noted that this decision "removes choice by causing barriers to access" and will leave parents unsure who to trust for vaccine recommendations. The change also adds unnecessary complexity, as healthcare providers may interpret the new language as a sign that the vaccine is controversial or carries additional risks.
Independent medical bodies like the American Academy of Pediatrics strongly recommend that all infants receive the hepatitis B vaccine within 24 hours of birth. However, under the new recommendation, parents may delay vaccination, potentially leaving them vulnerable to infection.
The CDC's action aligns with President Trump's stated desire to review and realign child immunization recommendations with best practices from other developed countries. However, this move is seen as a regressive step in public health policy, driven by misinformation and misconceptions about vaccines.
As Cody Meissner, professor of pediatrics at Dartmouth College, noted, "We have heard 'do no harm' is a moral imperative. We are doing harm by changing this wording." The decision highlights the need for evidence-based policies that prioritize public health over politics and special interests.